Per a new Nature Biotech article, scientists have re-engineered Akt1 enzyme to provoke a prolonged immune response to cancer.
This by extension suggests that inhibiting Akt1 has an immune-supressing effect, and perhaps inhibiting other genes in the Akt pathway have the same effect.
Showing posts with label Akt. Show all posts
Showing posts with label Akt. Show all posts
Sunday, December 17, 2006
Thursday, November 16, 2006
This time anti-inflammatory has anti-cancer effect
I didn't go looking for this theme, but funny enough my first article today is a mirror image of yesterday's last article......
Researchers at Ohio State have developed a new oncology therapeutic derived from the same chemical structure as Celebrex, which was previously noted to have an anti-cancer effect. The derivative compound (lead: OSU-03012) shares lineage with other COX-2 inhibitors.
It turns out the new compound and Celebrex inhibit Akt, which has long been a target of interest for pharma. (I don't know why prior Akt efforts have failed - was it toxicity? If, watch interest in Akt ramp up with the identification of safe Akt inhibitors based on COX-2 inhibitors.)
Researchers at Ohio State have developed a new oncology therapeutic derived from the same chemical structure as Celebrex, which was previously noted to have an anti-cancer effect. The derivative compound (lead: OSU-03012) shares lineage with other COX-2 inhibitors.
It turns out the new compound and Celebrex inhibit Akt, which has long been a target of interest for pharma. (I don't know why prior Akt efforts have failed - was it toxicity? If, watch interest in Akt ramp up with the identification of safe Akt inhibitors based on COX-2 inhibitors.)
Subscribe to:
Posts (Atom)
